Leflunomide as adjuvant treatment of dermatomyositis.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 18194823.
- Also identified by DOI 10.1016/j.jaad.2007.08.014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report 3 cases of recalcitrant dermatomyositis that responded to the addition of daily leflunomide, a novel immunomodulatory drug that is currently used to treat rheumatoid arthritis. In our patients, leflunomide proved both safe and effective as adjuvant therapy in treating dermatomyositis.
Medical subject headings
- Adjuvants, Immunologic
- Dermatomyositis
- Isoxazoles